AbCellera’s Q4 EPS Loss Narrows 83%, Revenue Up $39.8M Sparks 9% Jump
AbCellera Biologics shares surged 9.32% to $3.52 in after-hours trading following Q4 2025 results that delivered an EPS loss of $0.03 versus a consensus loss of $0.18. Revenue rose by $39.8 million year-over-year, reversing the prior quarter’s shortfall.
1. Q4 2025 Earnings Results
AbCellera reported a fourth-quarter EPS loss of $0.03, beating the consensus loss estimate of $0.18 by 83.33%. The company’s revenue rose by $39.8 million year-over-year, marking a significant rebound after a prior quarter earnings miss.
2. After-Hours Market Reaction
Shares of AbCellera jumped 9.32% in after-hours trading to $3.52, following a 6.27% gain to $3.22 at the close. The surge reflects investor optimism around the earnings beat and strengthened revenue trajectory.
3. Trading Metrics and Positioning
AbCellera’s market capitalization stands at $963.9 million, with a 52-week trading range of $1.89 to $6.52. The stock has gained 14.18% over the past 12 months and currently trades 28.7% above its annual low, with an RSI of 44.92.